A recent study published in the Journal of the American Medical Association estimates that over 40% of the U.S. population will develop metabolic dysfunction–associated steatotic liver disease (MASLD), commonly known as fatty liver, by 2050—equating to approximately 122 million adults. This number is both astounding and concerning, especially as fatty liver disease is rapidly becoming one of the leading causes of liver transplants—and a new liver isn’t easy to come by. In fact, the study predicts that liver cancer cases will double, while the need for liver transplants will quadruple. This raises an urgent question: What is being done to…